Andera Partners

Andera Partners is a Paris-based private equity firm founded in 2001 that invests in unlisted companies in France and internationally. The firm focuses on growth-stage opportunities, primarily through buyouts, and manages over €2 billion in investments across life sciences, growth capital, and sponsorless mezzanine debt. It targets sectors including sustainable energy, transportation and logistics, agribusiness, business-to-business and business-to-consumer, building and construction, cosmetics, distribution, industry, information technology and software, media, medical technology, real estate, therapeutic products, and tourism.

Sirsa, established in 2014 and based in Paris, France, is a consulting firm focused on sustainable transformation. The company specializes in evaluating existing processes and analyzing risks to define strategies for transforming operations. Sirsa offers a comprehensive suite of services that includes implementing strategic plans, managing action plans, reporting results, and providing compliance services. The firm caters to a diverse range of industries, including aerospace, defense, food products, electrical equipment, healthcare, energy, medical supplies, environmental, and software sectors. In addition, Sirsa has developed a software-as-a-service (SAAS) platform that measures companies' extra-financial footprint and impacts, further enhancing its commitment to sustainability and operational effectiveness.

Bioclinic operates a network of medical analysis laboratories in the Ile-de-France region, serving health professionals, hospitals, clinics, care centers, and retirement homes. Founded in 1995 and based in Paris, the company specializes in areas such as molecular biology, genetics, antibiotic resistance, and reproductive health. By focusing on these fields, Bioclinic aims to provide clients and their patients with enhanced medical diagnostic results.

GLOBE Groupe sa is a Paris-based advertising agency that specializes in strategic marketing and communication services. The company focuses on shopper marketing to create impactful consumer experiences that drive sales. It offers a range of services including strategic planning, non-media planning, talent casting, recruitment, training, payroll, and logistics such as storage, dispatch, and cold-chain management. GLOBE Groupe also implements marketing activation campaigns and provides tools for performance measurement, utilizing key performance indicators to assess the effectiveness of its strategies. The firm caters to various sectors including consumer goods, media, retail, and recruitment, ensuring that its clients can adapt to the evolving landscape of consumer behavior and promotional messaging. Through its secure online platform, myGLOBE, clients can monitor operations in real-time, enhancing transparency and communication throughout the marketing process.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Cellectis is a clinical-stage biotechnology company specializing in immuno-oncology. It develops allogeneic T-cell therapies using gene-editing technologies, focusing on chimeric antigen receptor (CAR) T-cells targeting various cancers.

Cellectis is a clinical-stage biotechnology company specializing in immuno-oncology. It develops allogeneic T-cell therapies using gene-editing technologies, focusing on chimeric antigen receptor (CAR) T-cells targeting various cancers.